When a Flagship Health Tech Deal Meets Real-World Resistance
Every so often a piece of technology arrives with enormous fanfare, big promises, and a hefty price tag, only to face a wall of skepticism from the people actually expected to use it. That is the story unfolding across England’s National Health Service right now. Freedom of information responses gathered by the campaign group Medact reveal that a growing number of NHS organisations are declining to use Palantir’s £330m federated data platform, the FDP, or are trying it out and quietly going back to the systems they already had.
The platform has been live since March 2024, and it has its defenders. Some health bodies say it has made waiting lists easier to manage and improved how surgeries get scheduled. Palantir points to NHS figures showing trusts using the tool have carried out 117,000 additional operations and cut discharge delays for long-stay patients by 14.3 percent. NHS England has been careful to add a caveat, however, noting that these numbers cannot prove cause and effect because other variables were never controlled for.
Why Sixteen Hospitals Said No Thanks
The reasons trusts give are refreshingly direct. The University Hospitals of North Midlands said the platform does not appear to offer anything beyond what it already has. Greater Manchester’s care board called the system duplicative and retrograde. Birmingham’s University Hospitals, which looks after more than two million people, cited limited expected benefit over existing solutions. Across more than two dozen responses, sixteen trusts and health boards reported they do not use the platform at all. That is a striking number for a programme meant to bring the health service’s data together under one roof.
The debate goes well beyond spreadsheets. Palantir’s wider contracts with the Israeli military and Donald Trump’s homeland security agencies have fuelled protests, and more than 44,000 people have filed legal objections to their health records being used by the platform. The National Data Guardian, Dr Nicola Byrne, has urged ministers to weigh the “trust factor” heavily as the government decides whether to use a break clause in the seven-year contract. Two parliamentary select committees have also called for the deal to end. Palantir, for its part, accuses critics of slanted analysis and insists the platform is objectively successful.
What This Means for Patients and the Tech Market
For patients, the stakes are simple: their data, their waiting times, and their care. The fight over who builds the software that handles that information matters just as much as the software itself. Supporters of the Palantir approach argue that a single, centrally run system brings consistency. Critics counter that the NHS should instead focus on interoperability, letting each trust choose its own tools while agreeing common standards so they can talk to one another. Sophie Don of Voror, a company that lost the bid to Palantir, put it bluntly: there are home-grown systems that could deliver more value.
This story also carries a lesson for anyone who buys technology, whether a hospital administrator or a shopper choosing a new laptop. Big names and big promises do not automatically translate into daily usefulness. Real adoption depends on whether people who use a product every day find it genuinely better than what they had before. When frontline users vote with their feet, the market notices, and consumers everywhere should pay attention to the same signals. Before you commit your money or your data to any new platform, look for independent evidence, listen to the people already using it, and ask whether it solves a problem you truly have. That kind of informed decision making is what separates a smart purchase from an expensive regret.
